Clinical Trial

Study on Plasmablastic Lymphoma Patients

Study acronym: FIL_PlaLy
Recruiting
View on ClinicalTrials.gov →
Summary
This is an observational, multicenter, international and retrospective study, that aims to collect data on clinical and pathological characteristics, treatment regimens, outcome, and prognostic factors (clinical, biomarkers and/or radio-metabolic) in patients affected by PBL.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-13; most recent amendment 2025-12-01.
Status change: Not Yet Recruiting → Recruiting 2025-05-29
Trial Details
NCT Number NCT06781359
Lead Sponsor Fondazione Italiana Linfomi - ETS
Collaborators: AIL Roma - Italia, AIL Cuneo - Italia
Conditions Plasmablastic Lymphoma
Enrollment 200 participants
Start Date 2025-02-14
Primary Completion 2028-02-01 (estimated)
Study Completion 2028-02-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-02